This segment focuses on the development, manufacturing, and commercialization of diagnostic tests for Acute Kidney Injury (AKI), primarily utilizing the NGAL (Neutrophil Gelatinase-Associated Lipocalin) biomarker. Research and development activities include assay development, clinical validation studies, and collaborations with research institutions to improve the accuracy and efficiency of AKI detection. The ProNephro AKI (NGAL) assay is a key product, providing clinicians with a tool to assess kidney function and risk. This segment addresses the critical need for early and accurate AKI diagnosis, impacting patient outcomes by enabling timely interventions and reducing the risk of chronic kidney disease. BioPorto's market positioning is strengthened by its FDA-cleared ProNephro AKI assay, offering a competitive advantage in the AKI diagnostics market. Future opportunities include expanding the product portfolio, exploring new biomarkers, and expanding into new geographic markets. Regulatory and clinical aspects involve obtaining and maintaining regulatory approvals, conducting clinical trials, and adhering to quality standards. Partnerships with Beckman Coulter and other distributors are crucial for market access and global reach.

This segment involves the production and sale of monoclonal antibodies for research, pharmaceutical, and clinical use. Research and development activities include antibody discovery, characterization, and optimization. The company utilizes its expertise in antibody development to create a diverse portfolio of antibodies for various applications. These antibodies are used in scientific research, drug discovery, and diagnostic testing. The segment's focus is on providing high-quality antibodies to researchers and pharmaceutical companies worldwide. This segment supports advancements in various therapeutic areas, including oncology, immunology, and infectious diseases. BioPorto's market positioning is enhanced by its expertise in antibody production and its ability to provide custom antibody development services. Future opportunities include expanding the antibody portfolio, developing new antibody-based diagnostic tests, and entering into strategic partnerships with pharmaceutical companies. Regulatory aspects involve compliance with quality standards and obtaining necessary certifications. The company collaborates with research institutions and pharmaceutical companies to develop and commercialize antibody-based products.